Early eculizumab use in atypical haemolytic uraemic syndrome in a Jehovah’s Witness refusing blood products

Thrombotic microangiopathy (TMA) is characterized by microscopic angiopathic haemolytic anaemia, thrombocytopenia and organ injury. Supportive therapies include the use of blood products. Recently the terminal complement inhibitor eculizumab has been approved in atypical haemolytic uraemic syndrome...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Shaghana, May, Bentall, Andrew, Jesky, Mark D., Lester, William, Lipkin, Graham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471596/
https://www.ncbi.nlm.nih.gov/pubmed/28638625
http://dx.doi.org/10.1093/omcr/omx025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471596/
https://www.ncbi.nlm.nih.gov/pubmed/28638625
http://dx.doi.org/10.1093/omcr/omx025

Ejemplares similares